Similar articles

• A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders.

  Gray RE, Doherty SM, Galloway J, Coulton L, de Broe M, Kanis JA. Gray RE, et al. Arthritis Rheum. 1991 Mar;34(3):287-95. doi: 10.1002/art.1780340306. Arthritis Rheum. 1991. PMID: 2003854 Clinical Trial.
• Effect of low doses of deflazacort vs prednisone on bone mineral content in premenopausal rheumatoid arthritis.

  Messina OD, Barreira JC, Zanchetta JR, Maldonado-Cocco JA, Bogado CE, Sebastián ON, Flores D, Riopedre AM, Redondo G, Lázaro A. Messina OD, et al. J Rheumatol. 1992 Oct;19(10):1520-6. J Rheumatol. 1992. PMID: 1464862 Clinical Trial.
• Long-term therapy with the new glucocorticosteroid deflazacort in rheumatoid arthritis. Double-blind controlled randomized 12-months study against prednisone.

  Eberhardt R, Krüger K, Reiter W, Gross W, Zwingers T. Eberhardt R, et al. Arzneimittelforschung. 1994 May;44(5):642-7. Arzneimittelforschung. 1994. PMID: 8024639 Clinical Trial.
• Deflazacort. A review of its pharmacological properties and therapeutic efficacy.

  Markham A, Bryson HM. Markham A, et al. Drugs. 1995 Aug;50(2):317-33. doi: 10.2165/00003495-199550020-00008. Drugs. 1995. PMID: 8521761 Review.
• Low-dose corticosteroids in rheumatoid arthritis. A meta-analysis of their moderate-term effectiveness.

  Saag KG, Criswell LA, Sems KM, Nettleman MD, Kolluri S. Saag KG, et al. Arthritis Rheum. 1996 Nov;39(11):1818-25. doi: 10.1002/art.1780391107. Arthritis Rheum. 1996. PMID: 8912503